Terlipressin contains 12 amino acids Gly-Gly-Gly-c[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Lys-Gly-NH2 and having a molecular weight of 1227.37 Dalton.
Terlipressin is a prodrug of lypressin, also known as lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half-life and increased selectivity for the V1 receptor . This selectivity makes it a potent vasopressor, meaning it can constrict blood vessels and increase blood pressure effectively .
Terlipressin is indicated for several medical conditions, including:
Terlipressin was first approved by the U.S. Food and Drug Administration (FDA) in September 2022 . It is available under various brand names, including Terlivaz . The drug is also available in several countries, including the United States, New Zealand, Australia, the European Union, India, Pakistan, and the UAE .